Related Experiment Video
Updated: Aug 4, 2026

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
Published on: April 10, 2018
Effect of passage history on dengue-2 virus replication in subpopulations of human leukocytes
Abstract:
Three passage levels of dengue-2 virus strain PR-159, obtained during the course of deriving the attenuated S-1 vaccine, were tested for their ability to replicate in subpopulations of human peripheral blood leukocytes: (i) 6th primary African green monkey kidney (PGMK) cell passage (parent virus); (ii) 19th PGMK cell passage of a small-plaque-forming clone derived from the parent virus (S-1 PGMK virus); and (iii) virus derived by four additional passages of the S-1 PGMK virus in diploid fetal rhesus lung cells (S-1 vaccine virus). Replication of these PR-159 viruses and another strain of dengue-2 virus adapted to Raji cells (16681-Raji virus) was measured in adherent and nonadherent mononuclear cells. All viruses except the S-1 PGMK virus replicated in monocytes. Occasional replication of the S-1 PGMK virus was associated with reversion to parent virus. The addition to the monocyte cultures of low concentrations of homologous dengue-2 antibody or non-neutralizing heterologous antibody increased the yield of the parent virus as much as 400-fold. This phenomenon of immune enhancement usually enabled the S-1 PGMK virus to replicate slowly in monocytes, but the progeny virus produced large plaques similar to the parent virus. Replication of the S-1 vaccine virus in cultured monocytes did not result in the appearance of large plaques. We could not recover S-1 vaccine virus from monocytes harvested from infected volunteers in the same manner that monocytes from natural human infections yield wild virus. The three passage levels of PR-159 virus were tested for replication in lymphocytes in comparison with the 16681-Raji virus. Only the 16681-Raji virus replicated in human lymphocytes cultured with or without enhancing antibody.
Insights
Dengue-2 virus vaccine development showed that while parent and vaccine viruses replicate in monocytes, only the adapted Raji cell virus replicates in lymphocytes. Immune enhancement can increase parent virus yield.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Dengue virus research focuses on developing attenuated vaccines for public health.
- Understanding virus replication in human immune cells is crucial for vaccine efficacy.
- Dengue-2 virus strain PR-159 was used to derive the S-1 vaccine.
Purpose of the Study:
- To investigate the replication of different Dengue-2 virus passage levels in human leukocyte subpopulations.
- To assess the role of immune enhancement in Dengue-2 virus replication.
- To compare the replication of vaccine candidate viruses with wild-type and adapted strains.
Main Methods:
- Culturing human peripheral blood leukocytes (monocytes and lymphocytes).
- Inoculating leukocyte cultures with Dengue-2 virus strains at various passage levels (parent, S-1 PGMK, S-1 vaccine, 16681-Raji).
- Measuring virus replication and plaque formation in infected cells.
- Evaluating the effect of homologous and heterologous antibodies on virus replication.
Main Results:
- Parent and S-1 vaccine viruses replicated in monocytes, while S-1 PGMK virus showed occasional replication linked to reversion.
- Immune enhancement significantly increased parent Dengue-2 virus yield in monocytes.
- Only the 16681-Raji virus demonstrated replication in human lymphocytes, with or without enhancing antibody.
- S-1 vaccine virus did not produce large plaques in monocytes, and was not recovered from infected volunteers' monocytes.
Conclusions:
- Dengue-2 virus vaccine candidate replication is cell-type specific within leukocytes.
- Immune enhancement plays a complex role in Dengue-2 virus replication dynamics.
- Further studies are needed to understand the in vivo behavior of the S-1 vaccine virus in human monocytes.
Related Concept Videos
Yellow Fever
Malaria

